Intellectual Property

We have a robust and growing intellectual property estate covering our mRNAi GOLD™ platform, including all aspects of siRNA modification, delivery, construct design, specific drug products and their uses.

As of March 2021, we solely owned 30 granted patents and have 106 pending patent applications. We expect our patent portfolio to continue to expand and mature over the next few years.

molecule arrows
siRNA Molecule

siRNA Molecule

We have developed chemical modification patterns that enhance stability and improve activity

Linker

Linker

We have developed proprietary linkers, enabling the attachment of targeting ligands to the siRNA molecule

GalNAc Ligand

GalNAc Ligand

We attach the GalNAc ligand to our siRNA molecule at one or more different sites for highly targeted delivery to specific liver tissues/cells